Supplemental Figure 1: Uveitis Survey

Patient D	Demographic Information							Uveitis Treatment					
	Age at onset of treatment (years)							Uveitis treatment that patient received					
	Gender												
	Male		C		Female								
	Male				Female		reset	Expand					
								Patient response to treatment					
	Race/Ethnicity White African American / Black												
	White			Africar	American /	Black							
	American Indian / Alaska Na	tive		Asian	/ Pacific Isla	nder							
	Hispanic / Latino				Other			Expand					
							reset	Clinical outcome and duration of followup					
Uveitis (Uveitis Clinical Summary												
	Type of Uveitis												
	Anterior uveitis			Inte	rmediate uvo	itis							
	Posterior uveitis				Panuveitis		\leq	Expand					
							\exists	Did patient have a previous history of uveitis prior to starting the drug of interest?					
	Optic neuritis			Other				Yes No					
							16561	reset					
	ICD-10 / ICD-9 Diagnosis Code (if available)							Checkpoint Inhibitor Drug Information					
								Which of the following drugs of interest was the patient administered? (select multiple if patient on					
	Date of Uveitis Diagnosis												
	Today M-D-Y												
	Date of Uveitis Resolution							Atezolizumab (Tecentriq)					
	Today M-D-Y							Durvalumab (Imfinzi) Ipilimumab (Yervoy), [CTLA-4 inhibitor]					
	Ilveitis clinical summary using Stan	dardization	of Uvoitic (S	UN) Nomen	clature			Cother					
	overtis chinical summary using stan	Gardization	or overlas (o	on) nomen	Jature			Current					
	Anterior chamber cell	0.5+	1+	2+	3+	4+	N/A	What was the drug dose and dosing regimen, if available?					
			0	0	0	0	reset						
			0	0	0	0	reset	Dates of Drug Treatment					
	Vitreous haze		0	0	0	0	reset						
	Compliantiana (astadall that analy)						reset						
	Date of Uveitis Resolution Date of Uveitis Resolution Uveitis clinical summary using Standardization Uveitis clinical summary using Standardization O.5+ Anterior chamber cell Anterior chamber flare Vitreous cell Vitreous cell Complications (select all that apply) Subretinal fluid Retinal detachment Vitreous hemorrhage			Manular	dama			IN ICORY M-U-Y					
				Macular			\leq	Date of last drug infusion					
	Retinal detachment			Optic net	iritis			Today M-D-Y					
	Vitreous hemorrhage		e	Neovasc	ular glaucom	а		Yes No Sheckpoint Inhibitor Drug Information reset Sheckpoint Inhibitor Drug Information Image: Sheckpoint Inhibitor Drug Information Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Nivolumab (Bavencio) Image: Durvalumab (Imfinzi) Image: Sheckpoint Inhibitor) Image: Durvalumab (Image: Sheckpoint Inhibitor) Image: Sheckpoint Inhibitor) Image: Durvalumab (Image: Sheckpoint Inhibitor) Image: Sheckpoint Inhibitor) Image: Durvalumab (Image: Sheckpoint Inhibitor) Image: Sheckpoint Inhibitor Ima					
	Other			None									
								Non small cell lung cancer					
								i con sinan cen lung cancer oquamous cen carbinona of neau anu neck					
								Urothelial carcinoma Renal cell carcinoma					
								Merkel cell carcinoma Microsatellite instability high or					
								mismatch repair deficient metastatic cancer					
								Other					

Supplemental Figure 1: Uveitis Survey

The online survey was designed and distributed through the secure electronic data collection tool REDCap. The survey consisted of 18 primary questions, with additional secondary questions requesting additional information displayed if specific responses were inputted. Deidentified patient data was collected, including questions regarding patient demographic information, uveitis clinical summary, uveitis treatment, and checkpoint inhibitor drug information. All responses were saved in HIPAA compliant data backup.